HIV Medicine

Papers
(The H4-Index of HIV Medicine is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-10-01 to 2024-10-01.)
ArticleCitations
Immune deficiency is a risk factor for severe COVID‐19 in people living with HIV125
Clinical characteristics of monkeypox virus infections among men with and without HIV: A large outbreak cohort in Germany69
Major revision version 11.0 of the European AIDS Clinical Society Guidelines 202162
Impact of coronavirus disease (COVID‐19) on HIV testing and care provision across four continents61
Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy48
The burden of non‐communicable diseases and mortality in people living with HIV (PLHIV) in the pre‐, early‐ and late‐HAART era39
Major revision version 12.0 of the European AIDS Clinical Society guidelines 202338
Clinical epidemiology and outcome of HIV‐associated talaromycosis in Guangdong, China, during 2011–201736
Managing HIV‐associated inflammation and ageing in the era of modern ART33
Chems4EU: chemsex use and its impacts across four European countries in HIV‐positive men who have sex with men attending HIV services32
Public understanding and awareness of and response to monkeypox virus outbreak: A cross‐sectional survey of the most affected communities in the United Kingdom during the 2022 public health emergency27
Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium27
BHIVA guidelines on antiretroviral treatment for adults living with HIV‐1 202226
Late diagnosis of HIV: An updated consensus definition25
Effectiveness and safety of dolutegravir two‐drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta‐analysis of real‐world evidence24
Qualitative assessment of anti‐SARS‐CoV‐2 spike protein immunogenicity (QUASI) after COVID‐19 vaccination in older people living with HIV24
Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long‐acting cabotegravir and rilpivirine in clinical trials23
Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor‐ to dolutegravir‐based antiretroviral therapy: A prospective cohort study in Lesotho (DO‐REAL study)23
Compassionate use of long‐acting cabotegravir plus rilpivirine for people living with HIV‐1 in need of parenteral antiretroviral therapy22
Efficacy and durability of two‐ vs. three‐drug integrase inhibitor‐based regimens in virologically suppressed HIV‐infected patients: Data from real‐life ODOACRE cohort22
COVID‐19 in hospitalized HIV‐positive and HIV‐negative patients: A matched study21
Comorbidities in women living with HIV: A systematic review21
0.019173860549927